Literature DB >> 25510276

Targeting the bone marrow microenvironment in multiple myeloma.

Yawara Kawano1, Michele Moschetta, Salomon Manier, Siobhan Glavey, Güllü T Görgün, Aldo M Roccaro, Kenneth C Anderson, Irene M Ghobrial.   

Abstract

Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow (BM). Despite the significant advances in treatment, MM is still a fatal malignancy. This is mainly due to the supportive role of the BM microenvironment in differentiation, migration, proliferation, survival, and drug resistance of the malignant plasma cells. The BM microenvironment is composed of a cellular compartment (stromal cells, osteoblasts, osteoclasts, endothelial cells, and immune cells) and a non-cellular compartment. In this review, we discuss the interaction between the malignant plasma cell and the BM microenvironment and the strategy to target them.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BMSCs; bone marrow; immune cells; myeloma; vessel formation

Mesh:

Substances:

Year:  2015        PMID: 25510276     DOI: 10.1111/imr.12233

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  135 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

4.  Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.

Authors:  Miki Furukawa; Hiroshi Ohkawara; Kazuei Ogawa; Kazuhiko Ikeda; Koki Ueda; Akiko Shichishima-Nakamura; Emi Ito; Jun-Ichi Imai; Yuka Yanagisawa; Reiko Honma; Shinya Watanabe; Satoshi Waguri; Takayuki Ikezoe; Yasuchika Takeishi
Journal:  J Biol Chem       Date:  2017-01-31       Impact factor: 5.157

Review 5.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

6.  Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.

Authors:  Francesca Fontana; Xia Ge; Xinming Su; Deep Hathi; Jingyu Xiang; Simone Cenci; Roberto Civitelli; Kooresh I Shoghi; Walter J Akers; Andre D'avignon; Katherine N Weilbaecher; Monica Shokeen
Journal:  Clin Cancer Res       Date:  2016-08-02       Impact factor: 12.531

Review 7.  Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.

Authors:  Arnab Ghosh; Ioannis Politikos; Miguel-Angel Perales
Journal:  Curr Opin Oncol       Date:  2017-11       Impact factor: 3.645

8.  Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.

Authors:  Monica Galli; Manik Chatterjee; Mariella Grasso; Giorgina Specchia; Hila Magen; Hermann Einsele; Ivana Celeghini; Paola Barbieri; David Paoletti; Silvia Pace; Ralph D Sanderson; Alessandro Rambaldi; Arnon Nagler
Journal:  Haematologica       Date:  2018-04-26       Impact factor: 9.941

9.  3d Tissue Engineered In Vitro Models Of Cancer In Bone.

Authors:  Anna M Sitarski; Heather Fairfield; Carolyne Falank; Michaela R Reagan
Journal:  ACS Biomater Sci Eng       Date:  2017-06-09

10.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.